| Literature DB >> 28357011 |
Ahmet Celik1, Nihat Kalay2, Hasan Korkmaz1, Orhan Dogdu2, Omer Sahin2, Deniz Elcik2, Seyhan Karacavus3, Ali Dogan2, Tugrul Inanc2, Ibrahim Ozdogru2, Abdurrahman Oguzhan2, Ramazan Topsakal2.
Abstract
BACKGROUND: Large randomized studies revealed that percutaneous coronary intervention has no clinical benefit in patients with total occlusion. The purpose of this study is to evaluate left ventricular remodelling after PCI for total and subtotal infarct-related left anterior desending artery in stable patients who have not received trombolytic theraphy.Entities:
Keywords: Left anterior descending artery; Left ventricular remodeling; Total and subtotal occlusion
Year: 2011 PMID: 28357011 PMCID: PMC5358283 DOI: 10.4021/cr83w
Source DB: PubMed Journal: Cardiol Res ISSN: 1923-2829
Baseline Characteristics of All Patients in Three Groups
| Total-PCI Group (n:18) | Total-Medical Group (n:19) | Subtotal-PCI Group (n:20) | P value | |
|---|---|---|---|---|
| Age | 62 ± 12 | 65 ± 8 | 59 ± 12 | 0.2 |
| Female (n,%) | 5 (27) | 6 (31) | 6 (30) | 0.9 |
| DM (n,%) | 8 (44) | 9 (47) | 4 (20) | 0.1 |
| HT (n,%) | 9 (50) | 10 (52) | 6 (30) | 0.3 |
| Smoke (n,%) | 11 (61) | 10 (52) | 12 (60) | 0.8 |
| CVD (n,%) | 1 (5) | 2 (10) | 0 | 0.3 |
| NYHA Class (n,%) | ||||
| I | 7 (39) | 8 (42) | 9 (45) | 0.9 |
| II | 11(61) | 11(58) | 11(55) | 0.9 |
| III- IV | 0 | 0 | 0 | |
| Blood Pressure (mmHg) | ||||
| Diastolic | 82 ± 18 | 85 ± 15 | 75 11 | 0.1 |
| Systolic | 133 ± 23 | 137 ± 28 | 125 ± 22 | 0.3 |
| Creatinine (mg/dl) | 1.0 ± 0.2 | 1.1 ± 0.4 | 0.9 ± 0.1 | 0.1 |
| Lipid profile (mg/dl) | ||||
| LDL-C | 120 ± 29 | 116 ± 43 | 118 ± 34 | 0.9 |
| HDL-C | 39 ± 9 | 41 ± 10 | 37 ± 8 | 0.4 |
| T.CHOL | 192 ± 46 | 183 ± 54 | 184 ± 42 | 0.8 |
| TG | 165 ± 131 | 129 ± 89 | 144 ± 80 | 0.5 |
Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. DM: diabetes mellitus, HT: hypertension, CVD: cerebrovascular disease, LDL-C: low density lipoprotein, HDL-C: high density lipoprotein, T.CHOL: total cholesterol, TG: triglyceride
The Change of Echocardiographic Parameters at Baseline and First Month in the Total-PCI Group
| Baseline | First month | p value | |
|---|---|---|---|
| LVSD (cm) | 3.4 ± 0.4 | 3.5 ± 0.4 | 0.1 |
| LVDD (cm) | 4.8 ± 0.4 | 4.9 ± 0.3 | 0.02 |
| LVESV (mL) | 59 ± 27 | 68 ± 26 | 0.03 |
| LVEDV (mL) | 98 ± 35 | 114 ± 35 | 0.01 |
| LVEF (%) | 39 ± 8 | 40 ± 8 | 0.1 |
| LV Mass (gr) | 198 ± 57 | 218 ± 54 | 0.005 |
| LAD (cm) | 3.6 ± 0.3 | 3.7 ± 0.2 | 0.03 |
| sPAP (mmHg) | 33 ± 12 | 34 ± 12 | 0.5 |
| E/E’ | 11±5 | 8±4 | 0.05 |
Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. LV: Left ventricular LVDD: Left ventricular diastolic diameter, LVSD: Left ventricular systolic diameter, LVEDV: Left ventricular enddiastolic volume, LVESV: Left ventricular endsystolic volume, LVEF: Left ventricular ejection fraction, LVM: Left ventricular mass, LAD: left atrial diameter, sPAP: systolic pulmonary artery pressure, E/E’: ratio of transmitral E velosity to myocardial E velosity
The Change of Echocardiographic Parameters at Baseline and First Month in the Total-Medical Group
| Baseline | First month | p value | |
|---|---|---|---|
| LVSD (cm) | 3.8 ± 0.5 | 3.8 ± 0.4 | 0.5 |
| LVDD (cm) | 5.0 ± 0.5 | 5.0 ± 0.4 | 0.3 |
| LVESV (mL/mm2) | 75 ± 23 | 82 ± 25 | 0.1 |
| LVEDV (mL/mm2) | 113 ± 27 | 126 ± 29 | 0.05 |
| LVEF (%) | 35 ± 9 | 36 ± 9 | 0.2 |
| LV Mass (gr) | 214 ± 67 | 235 ± 73 | 0.04 |
| LAD (cm) | 3.7 ± 0.4 | 3.7 ± 0.4 | 0.9 |
| sPAP (mmHg) | 38 ± 11 | 36 ± 9 | 0.2 |
| E/E’ | 10±4 | 8±3 | 0.02 |
Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. LV:Left ventricular LVDD: Left ventricular diastolic diameter, LVSD: Left ventricular systolic diameter, LVEDV: Left ventricular enddiastolic volume, LVESV: Left ventricular endsystolic volume, LVEF: Left ventricular ejection fraction, LVM: Left ventricular mass, LAD: left atrial diameter, sPAP: systolic pulmonary artery pressure, E/E’: ratio of transmitral E velosity to myocardial E velosity
The Change of Echocardiographic Parameters at Baseline and First Month in the Subtotal-PCI Group
| Baseline | First month | p value | |
|---|---|---|---|
| LVSD (cm) | 3.7 ± 0.5 | 3.8 ± 0.5 | 0.5 |
| LVDD (cm) | 5.0 ± 0.5 | 5.1 ± 0.5 | 0.2 |
| LVESV (mL/mm2) | 66 ± 30 | 68 ± 32 | 0.4 |
| LVEDV (mL/mm2) | 113 ± 40 | 115 ± 38 | 0.5 |
| LVEF (%) | 42 ± 9 | 42 ± 9 | 0.3 |
| LV Mass (gr) | 220 ± 59 | 231 ± 69 | 0.07 |
| LAD (cm) | 3.7 ± 0.5 | 3.7 ± 0.4 | 0.5 |
| sPAP (mmHg) | 32 ± 10 | 29 ± 10 | 0.02 |
| E/E’ | 9 ± 4 | 8 ± 3 | 0.1 |
Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. LV:Left ventricular LVDD: Left ventricular diastolic diameter, LVSD: Left ventricular systolic diameter, LVEDV: Left ventricular enddiastolic volume, LVESV: Left ventricular endsystolic volume, LVEF: Left ventricular ejection fraction, LVM: Left ventricular mass, LAD: left atrial diameter, sPAP: systolic pulmonary artery pressure, E/E’: ratio of transmitral E velosity to myocardial E velosity
Figure 1Percentage changes of echocardiographic parameters in three groups. P < 0.05 was accepted as a statistically significant. LV:Left ventricular LVDD: Left ventricular diastolic diameter, LVSD: Left ventricular systolic diameter, LVEDV: Left ventricular enddiastolic volume, LVESV: Left ventricular endsystolic volume, LVEF: Left ventricular ejection fraction.